Evaluation of prevalence and outcomes of serial tyrosine kinase inhibitor use in pediatric patients with advanced solid tumors.
Hannah E OlsenKevin X LiuA Lindsay FrazierAllison F O'NeillKatherine A JanewaySteven G DuBoisDavid S ShulmanPublished in: Pediatric blood & cancer (2023)
We observed a low response rate to mTKI rechallenge. However, we identified patients who had been treated with first mTKI for ≥4 months as more likely to have prolonged stable disease with second mTKI. Several patients had a response or stable disease on the second mTKI despite having progressed on the first mTKI. Though toxicity was common, only a minority of patients discontinued the second mTKI due to toxicity.